Pancreatic Cancer Research

ResearcherWashington University in St. LouisNo recent work listed

Dirk G. Brockstedt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0105-1761; OpenAlex author ID A5091820196. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers

Papers 8

  1. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
  2. Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-19-0650↗
  3. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  4. Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancrea… Co-author DOI 10.1186/2051-1426-3-s2-p102↗
  5. Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patient… Co-author DOI 10.1186/2051-1426-3-s2-p155↗
  6. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Co-author DOI 10.1200/jco.2014.57.4244↗
  7. A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with pre… Co-author DOI 10.1186/2051-1426-2-s3-p68↗
  8. Development of mutome-specific personalized vaccines for pancreatic cancer Co-author DOI 10.1186/2051-1426-1-s1-p224↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elizabeth M. Jaffee · 8 shared papers, 2013–2020 · strength 0.46
  2. Dung Thi Le · 7 shared papers, 2014–2020 · strength 0.42
  3. Todd S. Crocenzi · 5 shared papers, 2014–2020 · strength 0.27
  4. Nitya Nair · 3 shared papers, 2015–2020 · strength 0.23
  5. Chan C. Whiting · 3 shared papers, 2015–2020 · strength 0.23
  6. Andrew H. Ko · 3 shared papers, 2015–2020 · strength 0.20
  7. Daniel A. Laheru · 3 shared papers, 2015–2020 · strength 0.16
  8. Herbert J. Zeh · 3 shared papers, 2014–2019 · strength 0.14
  9. Andrea Wang‐Gillam · 3 shared papers, 2014–2019 · strength 0.14
  10. Vincent J. Picozzi · 3 shared papers, 2014–2019 · strength 0.14
  11. Robert H. Vonderheide · 2 shared papers, 2015–2020 · strength 0.13
  12. George Albert Fisher · 2 shared papers, 2015–2020 · strength 0.13
  13. Eric R. Lutz · 3 shared papers, 2013–2015 · strength 0.12
  14. Michael Andrew Morse · 2 shared papers, 2015–2019 · strength 0.11
  15. Lisa M. Coussens · 1 shared paper, 2020 · strength 0.08
  16. Robert A. Anders · 1 shared paper, 2020 · strength 0.08
  17. Elana Judith Fertig · 1 shared paper, 2020 · strength 0.08
  18. Annie A. Wu · 1 shared paper, 2020 · strength 0.08
  19. Takahiro Tsujikawa · 1 shared paper, 2020 · strength 0.08
  20. Margaret A. Tempero · 1 shared paper, 2020 · strength 0.08
  21. Kim A. Reiss · 1 shared paper, 2020 · strength 0.08
  22. Robert Lance Fine · 2 shared papers, 2014–2015 · strength 0.07
  23. Zev A. Wainberg · 1 shared paper, 2019 · strength 0.07
  24. Dan A. Laheru · 1 shared paper, 2019 · strength 0.07
  25. Noelle K. LoConte · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.